Losarstad Comp 100 mg / 12.5 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

losarstad comp 100 mg / 12.5 mg tabletti, kalvopäällysteinen

stada arzneimittel ag - hydrochlorothiazide, losartan potassium - tabletti, kalvopäällysteinen - 100 mg / 12.5 mg - losartaani ja diureetit

Valsarstad 40 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

valsarstad 40 mg tabletti, kalvopäällysteinen

stada arzneimittel ag - valsartan - tabletti, kalvopäällysteinen - 40 mg - valsartaani

Valsarstad 80 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

valsarstad 80 mg tabletti, kalvopäällysteinen

stada arzneimittel ag - valsartan - tabletti, kalvopäällysteinen - 80 mg - valsartaani

Valsarstad 160 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

valsarstad 160 mg tabletti, kalvopäällysteinen

stada arzneimittel ag - valsartan - tabletti, kalvopäällysteinen - 160 mg - valsartaani

Valsarstad 320 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

valsarstad 320 mg tabletti, kalvopäällysteinen

stada arzneimittel ag - valsartan - tabletti, kalvopäällysteinen - 320 mg - valsartaani

Candesarstad 4 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

candesarstad 4 mg tabletti

stada arzneimittel ag - candesartan cilexetil - tabletti - 4 mg - kandesartaani

Candesarstad 8 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

candesarstad 8 mg tabletti

stada arzneimittel ag - candesartan cilexetil - tabletti - 8 mg - kandesartaani

Candesarstad 16 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

candesarstad 16 mg tabletti

stada arzneimittel ag - candesartan cilexetil - tabletti - 16 mg - kandesartaani

Candesarstad 32 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

candesarstad 32 mg tabletti

stada arzneimittel ag - candesartan cilexetil - tabletti - 32 mg - kandesartaani

Comirnaty Euroopan unioni - suomi - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.